Morgan Stanley
HUMA icon

Morgan Stanley’s Humacyte HUMA Stock Holding History

Morgan Stanley’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
345,122
+158,379
+85% +$147K ﹤0.01% 5817
2026
Q1 		$113K Sell
186,743
-2,318,685
-93% -$2.41M ﹤0.01% 6107
2025
Q4 		$2.41M Buy
2,505,428
+408,675
+19% +$579K ﹤0.01% 4679
2025
Q3 		$3.65M Buy
2,096,753
+720,158
+52% +$1.41M ﹤0.01% 4390
2025
Q2 		$2.88M Buy
1,376,595
+796,225
+137% +$1.53M ﹤0.01% 4475
2025
Q1 		$990K Sell
580,370
-35,414
-6% -$133K ﹤0.01% 5004
2024
Q4 		$3.11M Buy
615,784
+56,471
+10% +$279K ﹤0.01% 4372
2024
Q3 		$3.04M Buy
559,313
+356,182
+175% +$2.35M ﹤0.01% 4355
2024
Q2 		$975K Buy
203,131
+62,800
+45% +$327K ﹤0.01% 4972
2024
Q1 		$436K Sell
140,331
-13,394
-9% -$45K ﹤0.01% 5374
2023
Q4 		$437K Buy
153,725
+75,420
+96% +$194K ﹤0.01% 5361
2023
Q3 		$229K Sell
78,305
-14,365
-16% -$47.5K ﹤0.01% 5519
2023
Q2 		$265K Buy
92,670
+17,025
+23% +$61.4K ﹤0.01% 5515
2023
Q1 		$234K Buy
75,645
+26,586
+54% +$75.6K ﹤0.01% 5639
2022
Q4 		$104K Buy
49,059
+2,091
+4% +$6.35K ﹤0.01% 5958
2022
Q3 		$153K Buy
46,968
+6,825
+17% +$26.2K ﹤0.01% 5860
2022
Q2 		$129K Sell
40,143
-2,460
-6% -$13.7K ﹤0.01% 6137
2022
Q1 		$300K Sell
42,603
-49,214
-54% -$287K ﹤0.01% 5697
2021
Q4 		$666K Buy
91,817
+19,474
+27% +$193K ﹤0.01% 5377
2021
Q3 		$840K Buy
72,343
+72,148
+36,999% +$825K ﹤0.01% 5161
2021
Q2 		$2K Sell
195
-55
-22% -$567 ﹤0.01% 7524
2021
Q1 		$3K Buy
+250
New +$2.73K ﹤0.01% 7213

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's HUMA Position: Q2 2026 in Review

Morgan Stanley increased its Humacyte (HUMA) stake by 85% in Q2 2026, buying an estimated $147K and bringing the position to 345,122 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #5817.

Morgan Stanley first reported a position in HUMA in Q1 2021 and has held it in 22 quarters since. The position peaked at $3.65M in Q3 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Morgan Stanley held 345,122 shares of Humacyte worth $269K as of Q2 2026.
  • Morgan Stanley bought 158,379 Humacyte shares in Q2 2026, an estimated $147K.
  • Humacyte made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5817 holding.
  • Morgan Stanley first reported a position in Humacyte in Q1 2021 and has held it in 22 quarters since.
  • Morgan Stanley's Humacyte position peaked at $3.65M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.